Avalo Therapeutics, Inc.
AVTX
$4.78
-$0.10-2.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 192.00K | 249.00K | 0.00 | -- | 571.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 192.00K | 249.00K | 0.00 | -- | 571.00K |
| Cost of Revenue | 5.54M | 6.50M | 2.86M | 387.00K | 424.00K |
| Gross Profit | -5.35M | -6.25M | -2.86M | -387.00K | 147.00K |
| SG&A Expenses | 5.23M | 4.29M | 4.53M | 3.19M | 2.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.50M | 13.11M | 9.47M | 5.23M | 4.32M |
| Operating Income | -13.31M | -12.86M | -9.47M | -5.23M | -3.75M |
| Income Before Tax | -35.23M | 23.02M | 98.47M | -121.28M | -8.18M |
| Income Tax Expenses | 114.00K | -14.00K | 7.00K | 7.00K | -9.00K |
| Earnings from Continuing Operations | -35.34M | 23.04M | 98.46M | -121.29M | -8.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.34M | 23.04M | 98.46M | -121.29M | -8.17M |
| EBIT | -13.31M | -12.86M | -9.47M | -5.23M | -3.75M |
| EBITDA | -13.24M | -12.83M | -9.44M | -5.19M | -3.71M |
| EPS Basic | -3.44 | 0.98 | 0.93 | -31.63 | -10.12 |
| Normalized Basic EPS | -2.15 | 2.59 | 2.63 | -68.18 | -3.31 |
| EPS Diluted | -3.44 | -2.83 | -3.86 | -31.63 | -20.23 |
| Normalized Diluted EPS | -2.15 | 1.33 | 2.63 | -68.18 | -3.31 |
| Average Basic Shares Outstanding | 10.23M | 5.55M | 23.39M | 859.40K | 807.40K |
| Average Diluted Shares Outstanding | 10.23M | 10.78M | 23.39M | 859.40K | 807.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |